白癜风靶向治疗的研究进展

Update on therapeutic targets for vitiligo therapy

白癜风是一种皮肤黏膜色素脱失为特征的获得性自身免疫性皮肤病。炎症细胞因子,如干扰素(IFN)-γ、白细胞介素(IL)-17、肿瘤坏死因子(TNF)-α、IL-6、IL-8、IL-21、IL-33、磷酸二酯酶(PDE)-4及转化生长因子(TGF)-β,在该病的进展中起着重要的作用,特别是IFN-γ/趋化因子配体(CXCL)10轴。近年来,靶向治疗通过调节与白癜风发病机制相关的细胞因子及其相应受体,对其治疗发挥了重要作用,JAK抑制剂及其与光疗联合治疗已被临床证实具有较好的治疗前景。本文全面评估各种生物制剂在白癜风治疗中的疗效和个体化用药选择,以期为临床药物治疗决策提供参考。

Vitiligo is a dermatological condition of autoimmune origin,characterized by the acquired loss of pigmentation in the skin and mucous membranes.Inflammatory cytokines,including interferon(IFN)-γ,interleukin(IL)-17,tumor necrosis factor(TNF)-α,IL-6,IL-8,IL-21,IL-33,phosphodiester enzyme(PDE)-4,and transforming growth factor(TGF)-β,play a crucial role in the progression of vitiligo.Among these,the IFN-γ/chemokine ligand(CXCL)10 axis is particularly significant.In recent times,the advent of targeted therapeutic approaches,focusing on modulating cytokines and their corresponding receptors implicated in the pathogenesis of vitiligo,has assumed paramount significance.JAK inhibitors and their combination therapy with phototherapy have been clinically proven to have promising therapeutic prospects.This review undertakes a comprehensive appraisal of the therapeutic efficacy and tailored drug selection pertaining to diverse biological agents employed in the management of vitiligo,aiming to provide valuable insights for clinical therapeutic decisions.